These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 577299

  • 1. Interaction between bromocriptine and levodopa. Biochemical basis for an improved treatment for parkinsonism.
    Hutt CS, Snider SR, Fahn S.
    Neurology; 1977 Jun; 27(6):503-10. PubMed ID: 577299
    [Abstract] [Full Text] [Related]

  • 2. Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
    Rinne UK, Marttila R.
    Ann Neurol; 1978 Sep; 4(3):263-7. PubMed ID: 718139
    [Abstract] [Full Text] [Related]

  • 3. Comparison between lergotrile and bromocriptine in parkinsonism.
    Teychenne PF, Pfeiffer RF, Bern SM, McInturff D, Calne DB.
    Ann Neurol; 1978 Apr; 3(4):319-24. PubMed ID: 666273
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacotherapy: problems and practices.
    Muenter MD.
    Clin Neuropharmacol; 1986 Apr; 9 Suppl 1():S23-36. PubMed ID: 3708606
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Normalization of brain serotonin by L-tryptophan in levodopa-treated rats.
    Fahn S, Snider S, Prasad AL, Lane E, Makadon H.
    Neurology; 1975 Sep; 25(9):861-5. PubMed ID: 1172210
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bromocriptine and lisuride in Parkinson disease.
    Lieberman AN, Gopinathan G, Neophytides A, Leibowitz M, Walker R, Hiesiger E.
    Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164
    [Abstract] [Full Text] [Related]

  • 12. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA, Weiner N.
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [Abstract] [Full Text] [Related]

  • 13. [Biochemical bases of Parkinson disease].
    Colucci d'Amato C, Puccini A, Cristillo A, Vizioli R.
    Recenti Prog Med; 1984 Oct; 75(10):889-901. PubMed ID: 6151219
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Bromocriptine in Parkinsonian syndromes. Results obtained in a group of patients treated for 8 months].
    Quattrini A, Paggi A, Del Pesce M, Di Bella P.
    Riv Patol Nerv Ment; 1978 Oct; 99(3):150-63. PubMed ID: 752907
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD, Delgado MR.
    Clin Neuropharmacol; 1985 Oct; 8(1):73-7. PubMed ID: 3978651
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.